Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against aspergillus fumigatus Academic Article uri icon


MeSH Major

  • Antifungal Agents
  • Aspergillosis
  • Lung Diseases, Fungal
  • Macrophage Colony-Stimulating Factor


  • The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence against Aspergillus. M-CSF (100-600 microg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P<0.001). PAMs harvested from rabbits treated with M-CSF had a significantly greater percent phagocytosis of Aspergillus fumigatus conidia than did PAMs from controls (P=0.04). These data indicate that prophylactic administration of M-CSF augments pulmonary host defence against A. fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia.

publication date

  • December 2001



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1006/cyto.2001.0889

PubMed ID

  • 11500084

Additional Document Info

start page

  • 87

end page

  • 95


  • 15


  • 2